| Identification | Back Directory | [Name]
Cophylline | [CAS]
142741-24-0 | [Synonyms]
Cophylline
Vinca alkaloid III-121C
[8,15'-Biaspidospermidine]-3,3'-dicarboxylicacid,2,2',3,3'-tetradehydro-6',7':7,16'-diepoxy-6,15-dihydroxy-16,17-dimethoxy-,dimethyl ester, (5a,6b,7a,8a,12R,19a)-(5'a,6'b,7'b,12'R,19'a)-
[8,15'-Biaspidospermidine]-3,3'-dicarboxylic acid, 2,2',3,3'-tetradehydro-6',7':7,16'-diepoxy-6,15-dihydroxy-16,17-dimethoxy-, dimethyl ester, (5α,6β,7α,8α,12R,19α)-(5'α,6'β,7'β,12'R,19'α)- | [Molecular Formula]
C44H50N4O10 | [MDL Number]
MFCD32000938 | [MOL File]
142741-24-0.mol | [Molecular Weight]
794.89 |
| Chemical Properties | Back Directory | [density ]
1.53±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
10.73±0.70(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Conophylline can be used in pharmacological activity and therapeutic use of differentiation of adipose-derived stem cells into functional islet-like cells using conophlline and nicotinamide. | [in vivo]
Conophylline (0.9 mg/kg; p.o.; daily; for 12 weeks) attenuates formation of the liver fibrosis induced by TAA in vivo[2].
| Animal Model: | Sprague-Dawley rats (70-80 g)[2] | | Dosage: | 0.9 mg/kg | | Administration: | Oral administration; daily; for 12 weeks | | Result: | Attenuated formation of the liver fibrosis induced by TAA. |
|
|
| Company Name: |
BioBioPha Co., Ltd.
|
| Tel: |
0871-65217109 13211707573; |
| Website: |
http://www.biobiopha.com |
|